What happened: 48 PLI Scheme for Bulk Drugs projects approved (KSMs/DIs/APIs)
The Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, approved 48 projects under the Production Linked Incentive (PLI) Scheme for Bulk Drugs—a scheme aimed at promoting domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs). The government also reported incentives and capacity creation status up to March 2026, including a list of APIs for which production has commenced.
Scheme scope, outlay, and reported utilisation status
The government stated the following financial and operational parameters for the PLI Scheme for Bulk Drugs:
Approved outlay: ₹6,940 crore.Incentive disbursement utilised (as of March 2026): ₹87.70 crore.Production capacity created: for 28 APIs/KSMs/DIs.Commercial production not achieved: 10 among the 28 items.
Investment against commitments (as of March 2026)
Related current affairs
- PLI bulk drugs scheme: approved API manufacturing projects in Telangana
- Update on incentives disbursed under PLI Schemes for Pharmaceuticals, Bulk Drugs and Medical Devices
- Schemes to strengthen pharmaceutical and bulk drug manufacturing in Maharashtra
- THE GIST: Centre approves National Investment Policy for Urea (NIPU)-2026
- Eye on supply chain, Cabinet approves Rs 1.27 lakh crore semiconductor push
- Global bids invited under PLI for 10 GWh ACC batteries